Pearl Therapeutics To Present Complete PT003 Results From Phase 2b COPD Study In A Late-Breaker Session At The American Thoracic Society
Pearl Therapeutics Inc. announced that complete results from the Company’s Phase 2b study of PT003 in patients with moderate-to-very severe COPD will be presented during a late-breaker poster session at the upcoming annual meeting of the American Thoracic Society (ATS)…
(more...)